NASDAQ:AMIX Autonomix Medical (AMIX) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free AMIX Stock Alerts $2.52 -0.17 (-6.32%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$2.40▼$2.6950-Day Range$2.66▼$3.4952-Week Range$2.40▼$7.60Volume137,771 shsAverage Volume60,543 shsMarket Capitalization$47.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Get Autonomix Medical alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Autonomix Medical Stock (NASDAQ:AMIX)Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Read More AMIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMIX Stock News HeadlinesMay 14 at 4:15 PM | globenewswire.comAutonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell SeriesMay 5, 2024 | seekingalpha.comAMIX Autonomix Medical, Inc.April 25, 2024 | finance.yahoo.comAutonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary MicrochipApril 24, 2024 | globenewswire.comAutonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarApril 16, 2024 | globenewswire.comAutonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related PainApril 15, 2024 | finance.yahoo.comAutonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment TechnologyApril 11, 2024 | benzinga.comAutonomix Medical (NASDAQ: AMIX) Is Cracking the Code Of The Peripheral Nervous System With Its Breakthrough Technology To Treat DiseasesApril 11, 2024 | uk.investing.comAutonomix Medical's study shows promise in renal treatmentApril 9, 2024 | globenewswire.comAutonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal DenervationApril 8, 2024 | globenewswire.comAutonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX TickerMarch 27, 2024 | globenewswire.comAutonomix to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 21, 2024 | uk.investing.comAutonomix Medical hires new Chief Business OfficerMarch 20, 2024 | globenewswire.comAutonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024March 19, 2024 | globenewswire.comAutonomix Appoints Jennifer Cook as Chief Business OfficerMarch 15, 2024 | marketwatch.comAutonomix Medical Shares Rise on First Three Patient Procedures CompletionMarch 14, 2024 | globenewswire.comAutonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer MarketMarch 6, 2024 | globenewswire.comAutonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer MarketMarch 1, 2024 | uk.investing.comAutonomix Medical Inc (AMIX)February 29, 2024 | globenewswire.comAutonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical TrialFebruary 23, 2024 | globenewswire.comAutonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix OpportunityFebruary 22, 2024 | finance.yahoo.comAutonomix Secures Principal Investigators and Completes Clinical Training for First Human StudyFebruary 21, 2024 | morningstar.comAutonomix Medical Inc AMIXFebruary 16, 2024 | globenewswire.comAutonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer MarketFebruary 14, 2024 | globenewswire.comAutonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key MilestonesSee More Headlines Receive AMIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autonomix Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/16/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:AMIX Previous SymbolNASDAQ:AMIX CUSIPN/A CIK1617867 Webautonomix.com Phone713-588-6150FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.29) per share Price / Book-8.69Miscellaneous Outstanding Shares18,794,000Free FloatN/AMarket Cap$47.36 million OptionableN/A BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Walter V. Klemp (Age 64)Executive Chairman Comp: $200kDr. Robert Schwartz M.D. (Age 72)Co-Founder & Chief Medical Officer Comp: $100kMr. Landy Toth (Age 46)Co-Founder & Chief Technology Officer Comp: $156.25kMs. Lori H. Bisson (Age 52)CEO & Director Mr. Trent N. Smith CPA (Age 55)Chief Financial Officer Ms. Jennifer CookChief Business OfficerMore ExecutivesKey CompetitorsInspireMDNYSE:NSPRIceCure MedicalNASDAQ:ICCMApyx MedicalNASDAQ:APYXCytosorbentsNASDAQ:CTSOMonogram OrthopaedicsNASDAQ:MGRMView All Competitors AMIX Stock Analysis - Frequently Asked Questions How have AMIX shares performed in 2024? Autonomix Medical's stock was trading at $5.20 at the beginning of the year. Since then, AMIX stock has decreased by 51.5% and is now trading at $2.52. View the best growth stocks for 2024 here. When did Autonomix Medical IPO? Autonomix Medical (AMIX) raised $11 million in an IPO on the week of January 29th 2024. The company issued 2,234,222 shares at $5.00 per share. When does the company's lock-up period expire? Autonomix Medical's lock-up period expires on Monday, July 29th. Autonomix Medical had issued 2,234,222 shares in its IPO on January 29th. The total size of the offering was $11,171,110 based on an initial share price of $5.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. How do I buy shares of Autonomix Medical? Shares of AMIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMIX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autonomix Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
